Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain | 44 | 2022 | 2175 | 6.340 |
Why?
|
Alcohol Drinking | 27 | 2022 | 805 | 5.280 |
Why?
|
Adolescent Behavior | 15 | 2020 | 264 | 3.570 |
Why?
|
Adolescent Development | 14 | 2022 | 28 | 3.310 |
Why?
|
Cognition | 21 | 2022 | 512 | 3.270 |
Why?
|
Underage Drinking | 10 | 2020 | 25 | 3.200 |
Why?
|
Marijuana Abuse | 14 | 2021 | 251 | 3.130 |
Why?
|
Alcoholism | 15 | 2022 | 1109 | 2.860 |
Why?
|
Substance-Related Disorders | 18 | 2022 | 1241 | 2.850 |
Why?
|
Ethanol | 16 | 2022 | 892 | 2.660 |
Why?
|
Adolescent | 74 | 2022 | 8903 | 2.550 |
Why?
|
Marijuana Smoking | 12 | 2020 | 108 | 2.410 |
Why?
|
Magnetic Resonance Imaging | 31 | 2021 | 2220 | 2.140 |
Why?
|
Alcohol-Related Disorders | 6 | 2018 | 95 | 1.870 |
Why?
|
Cannabis | 5 | 2021 | 115 | 1.640 |
Why?
|
Cerebral Cortex | 11 | 2020 | 415 | 1.610 |
Why?
|
Executive Function | 7 | 2021 | 106 | 1.590 |
Why?
|
Binge Drinking | 6 | 2020 | 50 | 1.410 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 2020 | 154 | 1.390 |
Why?
|
Memory, Short-Term | 5 | 2018 | 79 | 1.360 |
Why?
|
Child | 39 | 2022 | 6400 | 1.350 |
Why?
|
Therapy, Computer-Assisted | 2 | 2019 | 57 | 1.320 |
Why?
|
Avoidance Learning | 2 | 2019 | 58 | 1.320 |
Why?
|
Humans | 93 | 2022 | 68504 | 1.210 |
Why?
|
Neuropsychological Tests | 16 | 2020 | 517 | 1.160 |
Why?
|
White Matter | 5 | 2015 | 174 | 1.150 |
Why?
|
Acetylcysteine | 3 | 2019 | 296 | 1.120 |
Why?
|
Male | 67 | 2022 | 37265 | 1.100 |
Why?
|
Child Development | 3 | 2021 | 102 | 1.090 |
Why?
|
Female | 65 | 2022 | 38003 | 1.060 |
Why?
|
Young Adult | 28 | 2022 | 5708 | 0.980 |
Why?
|
Cues | 7 | 2019 | 654 | 0.960 |
Why?
|
Mental Disorders | 5 | 2021 | 659 | 0.940 |
Why?
|
Psychomotor Performance | 7 | 2015 | 213 | 0.940 |
Why?
|
Cannabidiol | 1 | 2021 | 31 | 0.830 |
Why?
|
Smoking Cessation | 8 | 2022 | 1030 | 0.800 |
Why?
|
Electronic Nicotine Delivery Systems | 2 | 2022 | 180 | 0.760 |
Why?
|
Autism Spectrum Disorder | 1 | 2021 | 111 | 0.730 |
Why?
|
Nerve Net | 3 | 2018 | 180 | 0.730 |
Why?
|
Attention | 5 | 2020 | 225 | 0.730 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2019 | 29 | 0.730 |
Why?
|
Memory | 5 | 2020 | 214 | 0.730 |
Why?
|
Proof of Concept Study | 2 | 2018 | 38 | 0.700 |
Why?
|
Minority Groups | 1 | 2020 | 196 | 0.700 |
Why?
|
Prejudice | 1 | 2019 | 37 | 0.700 |
Why?
|
Reward | 4 | 2020 | 200 | 0.690 |
Why?
|
Patient Advocacy | 1 | 2019 | 40 | 0.690 |
Why?
|
Racism | 1 | 2019 | 59 | 0.680 |
Why?
|
Organ Size | 6 | 2021 | 242 | 0.680 |
Why?
|
Medical Records | 1 | 2019 | 121 | 0.670 |
Why?
|
Neuroimaging | 5 | 2021 | 122 | 0.660 |
Why?
|
Students | 1 | 2020 | 233 | 0.650 |
Why?
|
Longitudinal Studies | 13 | 2021 | 1054 | 0.650 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 109 | 0.650 |
Why?
|
Tobacco Use Disorder | 2 | 2019 | 431 | 0.630 |
Why?
|
Visual Perception | 3 | 2018 | 124 | 0.620 |
Why?
|
Age Factors | 8 | 2019 | 1860 | 0.610 |
Why?
|
Free Radical Scavengers | 2 | 2019 | 112 | 0.600 |
Why?
|
Gray Matter | 5 | 2021 | 57 | 0.600 |
Why?
|
Motivation | 3 | 2019 | 561 | 0.570 |
Why?
|
Adult | 22 | 2022 | 21373 | 0.550 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 442 | 0.540 |
Why?
|
Brain Mapping | 6 | 2019 | 531 | 0.540 |
Why?
|
Receptors, Opioid, mu | 2 | 2014 | 70 | 0.530 |
Why?
|
Physicians | 1 | 2019 | 324 | 0.530 |
Why?
|
Tobacco Use | 4 | 2022 | 98 | 0.510 |
Why?
|
Pilot Projects | 6 | 2022 | 1341 | 0.510 |
Why?
|
Vaping | 3 | 2022 | 124 | 0.510 |
Why?
|
Psychology, Adolescent | 1 | 2014 | 38 | 0.500 |
Why?
|
Cognitive Dysfunction | 1 | 2017 | 176 | 0.490 |
Why?
|
Oxygen | 3 | 2018 | 386 | 0.470 |
Why?
|
Risk-Taking | 1 | 2015 | 210 | 0.470 |
Why?
|
Marijuana Use | 3 | 2018 | 35 | 0.470 |
Why?
|
Cross-Sectional Studies | 10 | 2021 | 2264 | 0.450 |
Why?
|
Double-Blind Method | 7 | 2021 | 1734 | 0.430 |
Why?
|
Family | 1 | 2014 | 293 | 0.430 |
Why?
|
Risk Factors | 8 | 2021 | 5719 | 0.420 |
Why?
|
Aging | 2 | 2015 | 909 | 0.410 |
Why?
|
Varenicline | 3 | 2021 | 98 | 0.410 |
Why?
|
Behavior, Addictive | 3 | 2019 | 317 | 0.400 |
Why?
|
Follow-Up Studies | 12 | 2019 | 3256 | 0.380 |
Why?
|
Narcotic Antagonists | 1 | 2012 | 184 | 0.380 |
Why?
|
Memory Disorders | 1 | 2011 | 111 | 0.380 |
Why?
|
Naltrexone | 1 | 2012 | 195 | 0.380 |
Why?
|
Prospective Studies | 13 | 2021 | 3702 | 0.370 |
Why?
|
Central Nervous System Depressants | 1 | 2011 | 182 | 0.370 |
Why?
|
Socioeconomic Factors | 5 | 2021 | 955 | 0.360 |
Why?
|
Sex Factors | 5 | 2016 | 1264 | 0.360 |
Why?
|
Glutamic Acid | 2 | 2022 | 332 | 0.340 |
Why?
|
Culture | 2 | 2019 | 75 | 0.310 |
Why?
|
Disease Susceptibility | 2 | 2021 | 179 | 0.300 |
Why?
|
Psychopathology | 3 | 2021 | 29 | 0.300 |
Why?
|
Machine Learning | 2 | 2019 | 170 | 0.290 |
Why?
|
Diffusion Tensor Imaging | 4 | 2015 | 211 | 0.280 |
Why?
|
Treatment Outcome | 7 | 2019 | 7026 | 0.280 |
Why?
|
Photic Stimulation | 2 | 2019 | 229 | 0.270 |
Why?
|
Proton Magnetic Resonance Spectroscopy | 2 | 2022 | 27 | 0.270 |
Why?
|
Pregnancy | 2 | 2020 | 2331 | 0.250 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2019 | 689 | 0.250 |
Why?
|
Impulsive Behavior | 2 | 2020 | 85 | 0.220 |
Why?
|
Choline | 1 | 2022 | 14 | 0.220 |
Why?
|
Domestic Violence | 1 | 2022 | 36 | 0.220 |
Why?
|
Gyrus Cinguli | 3 | 2021 | 113 | 0.210 |
Why?
|
Parents | 2 | 2022 | 309 | 0.210 |
Why?
|
Aspartic Acid | 1 | 2022 | 65 | 0.210 |
Why?
|
Mass Media | 1 | 2021 | 29 | 0.210 |
Why?
|
Sexual and Gender Minorities | 1 | 2022 | 37 | 0.210 |
Why?
|
Emotions | 3 | 2018 | 244 | 0.210 |
Why?
|
Cognition Disorders | 2 | 2015 | 342 | 0.210 |
Why?
|
Cyclonic Storms | 1 | 2021 | 58 | 0.210 |
Why?
|
Case-Control Studies | 3 | 2020 | 1548 | 0.210 |
Why?
|
Craving | 3 | 2022 | 200 | 0.200 |
Why?
|
Puberty | 1 | 2021 | 10 | 0.200 |
Why?
|
Sexual Maturation | 1 | 2021 | 10 | 0.200 |
Why?
|
Recreation | 1 | 2020 | 19 | 0.200 |
Why?
|
Cigarette Smoking | 2 | 2021 | 104 | 0.200 |
Why?
|
Gonadal Steroid Hormones | 1 | 2021 | 52 | 0.200 |
Why?
|
United States | 5 | 2022 | 7333 | 0.200 |
Why?
|
Child Behavior | 1 | 2020 | 56 | 0.190 |
Why?
|
Child of Impaired Parents | 1 | 2020 | 18 | 0.190 |
Why?
|
Intention | 1 | 2021 | 78 | 0.190 |
Why?
|
Research Design | 2 | 2019 | 729 | 0.190 |
Why?
|
School Health Services | 1 | 2020 | 72 | 0.190 |
Why?
|
Neural Inhibition | 1 | 2020 | 80 | 0.180 |
Why?
|
Schools | 1 | 2020 | 156 | 0.180 |
Why?
|
Flavoring Agents | 1 | 2019 | 24 | 0.180 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2021 | 208 | 0.180 |
Why?
|
Smoking | 2 | 2019 | 1448 | 0.180 |
Why?
|
Verbal Learning | 2 | 2016 | 29 | 0.180 |
Why?
|
Multimodal Imaging | 1 | 2019 | 62 | 0.180 |
Why?
|
False Negative Reactions | 1 | 2019 | 63 | 0.170 |
Why?
|
Bias | 1 | 2019 | 148 | 0.170 |
Why?
|
Neural Pathways | 1 | 2021 | 323 | 0.170 |
Why?
|
Bipolar Disorder | 1 | 2021 | 307 | 0.170 |
Why?
|
Medication Adherence | 2 | 2019 | 335 | 0.170 |
Why?
|
Anxiety Disorders | 1 | 2021 | 426 | 0.170 |
Why?
|
Affect | 3 | 2022 | 218 | 0.170 |
Why?
|
Anxiety | 1 | 2021 | 422 | 0.170 |
Why?
|
Prevalence | 2 | 2020 | 1609 | 0.170 |
Why?
|
Child Health | 1 | 2018 | 14 | 0.170 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 240 | 0.170 |
Why?
|
California | 1 | 2018 | 99 | 0.160 |
Why?
|
Wearable Electronic Devices | 1 | 2018 | 16 | 0.160 |
Why?
|
Program Evaluation | 1 | 2020 | 502 | 0.160 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2020 | 782 | 0.160 |
Why?
|
Alcohol Abstinence | 2 | 2015 | 23 | 0.160 |
Why?
|
Temperance | 1 | 2017 | 41 | 0.160 |
Why?
|
Health Services Research | 1 | 2019 | 209 | 0.160 |
Why?
|
Counseling | 1 | 2019 | 279 | 0.160 |
Why?
|
Cerebellum | 2 | 2020 | 103 | 0.150 |
Why?
|
Social Media | 1 | 2018 | 58 | 0.150 |
Why?
|
Prefrontal Cortex | 2 | 2020 | 637 | 0.150 |
Why?
|
Middle Aged | 8 | 2021 | 21115 | 0.150 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 951 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 1744 | 0.150 |
Why?
|
Internal-External Control | 1 | 2016 | 60 | 0.150 |
Why?
|
Behavior Therapy | 1 | 2019 | 297 | 0.140 |
Why?
|
Sleep Wake Disorders | 1 | 2017 | 94 | 0.140 |
Why?
|
Frontal Lobe | 2 | 2015 | 156 | 0.140 |
Why?
|
Breath Tests | 2 | 2015 | 23 | 0.140 |
Why?
|
Corpus Callosum | 1 | 2015 | 29 | 0.130 |
Why?
|
Neocortex | 1 | 2015 | 17 | 0.130 |
Why?
|
Pons | 1 | 2015 | 35 | 0.130 |
Why?
|
Social Environment | 1 | 2016 | 182 | 0.130 |
Why?
|
Sleep | 1 | 2017 | 263 | 0.130 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 1465 | 0.130 |
Why?
|
Health Services Accessibility | 1 | 2019 | 581 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 929 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 766 | 0.130 |
Why?
|
Functional Neuroimaging | 3 | 2021 | 82 | 0.120 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2013 | 49 | 0.120 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 2014 | 82 | 0.120 |
Why?
|
Telemedicine | 1 | 2022 | 698 | 0.120 |
Why?
|
Temporal Lobe | 1 | 2014 | 125 | 0.120 |
Why?
|
Amnesia, Retrograde | 1 | 2012 | 2 | 0.110 |
Why?
|
Drinking Behavior | 1 | 2012 | 20 | 0.110 |
Why?
|
Depression | 1 | 2019 | 942 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2014 | 627 | 0.110 |
Why?
|
Disulfiram | 1 | 2012 | 22 | 0.110 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2012 | 51 | 0.110 |
Why?
|
Taurine | 1 | 2012 | 51 | 0.110 |
Why?
|
Genetic Markers | 1 | 2012 | 144 | 0.100 |
Why?
|
Alleles | 1 | 2012 | 386 | 0.100 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2021 | 1506 | 0.100 |
Why?
|
Precision Medicine | 1 | 2012 | 111 | 0.100 |
Why?
|
Stress, Psychological | 1 | 2016 | 824 | 0.090 |
Why?
|
Animals | 2 | 2020 | 20849 | 0.090 |
Why?
|
Spatial Behavior | 1 | 2009 | 18 | 0.090 |
Why?
|
Language | 1 | 2009 | 120 | 0.080 |
Why?
|
Parietal Lobe | 2 | 2020 | 59 | 0.080 |
Why?
|
Regression Analysis | 1 | 2009 | 737 | 0.080 |
Why?
|
Aged | 4 | 2018 | 14841 | 0.080 |
Why?
|
Analysis of Variance | 3 | 2015 | 1039 | 0.080 |
Why?
|
Self Report | 2 | 2021 | 370 | 0.070 |
Why?
|
Disease Models, Animal | 1 | 2014 | 2548 | 0.070 |
Why?
|
Recurrence | 1 | 2009 | 948 | 0.070 |
Why?
|
Rats | 1 | 2014 | 5282 | 0.070 |
Why?
|
Comorbidity | 2 | 2019 | 1425 | 0.060 |
Why?
|
Tobacco Products | 2 | 2018 | 234 | 0.060 |
Why?
|
Reaction Time | 2 | 2018 | 170 | 0.060 |
Why?
|
Surveys and Questionnaires | 3 | 2018 | 2798 | 0.060 |
Why?
|
Sexuality | 1 | 2022 | 12 | 0.060 |
Why?
|
Peer Review | 1 | 2022 | 16 | 0.060 |
Why?
|
Sexism | 1 | 2022 | 11 | 0.060 |
Why?
|
Time Factors | 3 | 2017 | 4655 | 0.050 |
Why?
|
Parent-Child Relations | 1 | 2022 | 98 | 0.050 |
Why?
|
Dehydroepiandrosterone | 1 | 2021 | 29 | 0.050 |
Why?
|
Florida | 1 | 2021 | 221 | 0.050 |
Why?
|
Hobbies | 1 | 2020 | 4 | 0.050 |
Why?
|
Incidental Findings | 1 | 2021 | 42 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2022 | 179 | 0.050 |
Why?
|
Testosterone | 1 | 2021 | 96 | 0.050 |
Why?
|
Sports | 1 | 2020 | 55 | 0.050 |
Why?
|
Reference Values | 1 | 2021 | 579 | 0.050 |
Why?
|
Amygdala | 1 | 2021 | 159 | 0.050 |
Why?
|
Estradiol | 1 | 2021 | 173 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2022 | 652 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2021 | 303 | 0.050 |
Why?
|
Hallucinogens | 1 | 2019 | 14 | 0.040 |
Why?
|
Mindfulness | 1 | 2019 | 41 | 0.040 |
Why?
|
Drug Substitution | 1 | 2018 | 19 | 0.040 |
Why?
|
Dronabinol | 1 | 2019 | 84 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2019 | 100 | 0.040 |
Why?
|
Individuality | 1 | 2018 | 44 | 0.040 |
Why?
|
Family Therapy | 1 | 2019 | 82 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2021 | 383 | 0.040 |
Why?
|
Hippocampus | 1 | 2021 | 471 | 0.040 |
Why?
|
Southeastern United States | 1 | 2018 | 281 | 0.040 |
Why?
|
Exercise Therapy | 1 | 2019 | 183 | 0.040 |
Why?
|
Substance Abuse Detection | 1 | 2017 | 66 | 0.040 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2019 | 239 | 0.040 |
Why?
|
Ecological Momentary Assessment | 1 | 2016 | 16 | 0.040 |
Why?
|
Cannabinoids | 1 | 2017 | 90 | 0.040 |
Why?
|
Cerebrovascular Circulation | 1 | 2018 | 296 | 0.040 |
Why?
|
Risk | 1 | 2018 | 563 | 0.040 |
Why?
|
Tobacco Smoking | 1 | 2016 | 41 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 237 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2018 | 295 | 0.040 |
Why?
|
Decision Making | 1 | 2019 | 410 | 0.040 |
Why?
|
Urinalysis | 1 | 2015 | 27 | 0.030 |
Why?
|
Anisotropy | 1 | 2015 | 105 | 0.030 |
Why?
|
Age of Onset | 1 | 2015 | 188 | 0.030 |
Why?
|
Cohort Studies | 1 | 2021 | 2356 | 0.030 |
Why?
|
Patient Selection | 1 | 2019 | 592 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 785 | 0.030 |
Why?
|
Incidence | 1 | 2019 | 1581 | 0.030 |
Why?
|
Smokers | 1 | 2016 | 198 | 0.030 |
Why?
|
Minisatellite Repeats | 1 | 2014 | 16 | 0.030 |
Why?
|
Child, Preschool | 1 | 2021 | 3185 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2014 | 31 | 0.030 |
Why?
|
Arousal | 1 | 2014 | 168 | 0.030 |
Why?
|
South Carolina | 1 | 2020 | 2750 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2014 | 249 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 334 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2019 | 2077 | 0.030 |
Why?
|
Mental Health | 1 | 2015 | 278 | 0.030 |
Why?
|
Health Status | 1 | 2015 | 429 | 0.030 |
Why?
|
Genotype | 1 | 2014 | 785 | 0.030 |
Why?
|
Recovery of Function | 1 | 2015 | 506 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2019 | 7263 | 0.020 |
Why?
|